CRISPR Therapeutics Archives

News and Trends 6 Dec 2023

A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy

Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […]

December 6, 2023 - 6 minutesmins - By Willow Shah-Neville

In Depth 19 Jun 2023

Gene therapy: a promising solution for sickle cell disease

Sickle cell disease is debilitating, and many people who suffer with it find that their lives are defined by pain. This means a curative treatment would be completely life–altering, and, as we observe World Sickle Cell Day on June 19, we explore how gene therapy could be the most promising solution for curing sickle cell […]

June 19, 2023 - 6 minutesmins - By Willow Shah-Neville

News and Trends 26 Jan 2023

Milestone for gene-edited therapy for sickle cell disease

Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics have announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application of exa-cel for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The submission is supported by two global phase 3 studies investigating exa-cel as a potential one-time therapy for people with […]

January 26, 2023 - 3 minutesmins - By Jim Cornall

In Depth 20 Oct 2022

Opportunities and challenges for cell and gene therapy investments

Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […]

October 20, 2022 - 9 minutesmins - By Jonathan Smith

Best in Biotech 20 Dec 2021

The Billion-Euro European Biotech Companies in 2022

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]

December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin

In Depth 3 Nov 2021

CRISPR-Cas9: The Gene Editing Tool Changing the World

CRISPR-Cas9 has taken the world by storm with the promise of making gene editing much easier and faster than ever before. But how does CRISPR actually work? How can biology research benefit from it? What will happen when we start using it to edit human DNA? And what’s the fight between its developers all about? […]

November 3, 2021 - 11 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Oct 2021

Gene-Edited T Cell Therapy Players Battle Safety Doubts

Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused all clinical development following the detection of an unexpected genetic change in a clinical trial. Industry experts see these events as a reality check for the nascent field. Off-the-shelf treatments that use genetically engineered T cells to treat diseases suffered […]

October 22, 2021 - 5 minutesmins - By Anita Chakraverty

News and Trends 4 May 2021

Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe

Last month, the US firm bluebird bio abandoned the sale of its gene therapy Zynteglo in Germany after a pricing dispute with health authorities — a blow that could have repercussions for the rollout of other gene therapies in Europe. Zynteglo was approved in the EU in 2019 as the first-ever gene therapy for the […]

May 4, 2021 - 5 minutesmins - By Anita Chakraverty

Interview 3 Mar 2021

The Promises of CRISPR Genome Editing in Biomedicine

Tony Ho, Head of Research and Development at CRISPR Therapeutics, offers his insights into the advantages of CRISPR gene editing over other technologies and what the future holds for the genome editing field. For decades, gene editing required engineering DNA-cutting enzymes, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), for every specific […]

March 3, 2021 - 5 minutesmins - By Larissa Warneck-Silvestrin

Best in Biotech 11 Jan 2021

The 21 European Biotech Companies To Watch in 2021

As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year. There were many memorable moments for the European biotech industry in 2020. The Covid-19 pandemic took over the media and many […]

January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 17 Dec 2020

Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference

Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American Society of Hematology (ASH) displayed the achievements of many innovative treatments for blood conditions, including gene and cell therapies. A sweeping new wave of Covid-19 infections that is forcing new lockdowns across the northern hemisphere is already reshaping the biotech […]

December 17, 2020 - 6 minutesmins - By Victor Kotsev

crispr therapeutics vertex beta thalassemia

News and Trends 19 Nov 2019

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

CRISPR Therapeutics and its US partner Vertex Pharmaceuticals have released the first clinical results for a cell therapy made using the gene editing tool CRISPR/Cas9 in patients with genetic blood disorders. The interim results concern two patients enrolled in different phase I/II clinical trials testing the same therapy in two blood disorders: transfusion-dependent beta-thalassemia and […]

November 19, 2019 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us